{"id":4052,"date":"2021-10-01T06:12:27","date_gmt":"2021-10-01T06:12:27","guid":{"rendered":"https:\/\/www.maatpharma.com\/?page_id=4052"},"modified":"2026-04-15T16:21:30","modified_gmt":"2026-04-15T14:21:30","slug":"pipeline","status":"publish","type":"page","link":"https:\/\/www.maatpharma.com\/fr\/pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"4052\" class=\"elementor elementor-4052 elementor-3276\" data-elementor-settings=\"{&quot;element_pack_global_tooltip_width&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_widescreen&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_tablet_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_mobile_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_width_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;size&quot;:&quot;&quot;,&quot;sizes&quot;:[]},&quot;element_pack_global_tooltip_padding&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_widescreen&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_tablet_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_mobile_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_padding_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_widescreen&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_laptop&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_tablet_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_tablet&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_mobile_extra&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true},&quot;element_pack_global_tooltip_border_radius_mobile&quot;:{&quot;unit&quot;:&quot;px&quot;,&quot;top&quot;:&quot;&quot;,&quot;right&quot;:&quot;&quot;,&quot;bottom&quot;:&quot;&quot;,&quot;left&quot;:&quot;&quot;,&quot;isLinked&quot;:true}}\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-5619e710 elementor-section-height-min-height elementor-section-boxed elementor-section-height-default elementor-section-items-middle wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"5619e710\" data-element_type=\"section\" data-e-type=\"section\" id=\"row-bg-overlay\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;shape_divider_bottom&quot;:&quot;curve&quot;,&quot;shape_divider_bottom_negative&quot;:&quot;yes&quot;}\">\n\t\t\t\t\t\t\t<div class=\"elementor-background-overlay\"><\/div>\n\t\t\t\t\t\t<div class=\"elementor-shape elementor-shape-bottom\" aria-hidden=\"true\" data-negative=\"true\">\n\t\t\t<svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 1000 100\" preserveAspectRatio=\"none\">\n\t<path class=\"elementor-shape-fill\" d=\"M500,97C126.7,96.3,0.8,19.8,0,0v100l1000,0V1C1000,19.4,873.3,97.8,500,97z\"\/>\n<\/svg>\t\t<\/div>\n\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-325bbec4\" data-id=\"325bbec4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-33ba8c03 elementor-widget__width-initial elementor-invisible elementor-widget elementor-widget-heading\" data-id=\"33ba8c03\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInUp&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Pionniers de l\u2019approche \u00e9cosyst\u00e8me complet<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-41fe7de8 elementor-widget elementor-widget-heading\" data-id=\"41fe7de8\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">Nous d\u00e9veloppons une nouvelle classe de th\u00e9rapies \u00e0 base de microbiote,<br>\npour relever le d\u00e9fi d\u2019indications \u00e0 fort besoin m\u00e9dical en oncologie<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t<div class=\"elementor-element elementor-element-ec5a47a elementor-hidden-widescreen elementor-hidden-desktop elementor-hidden-laptop elementor-hidden-tablet_extra e-flex e-con-boxed wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-parent\" data-id=\"ec5a47a\" data-element_type=\"container\" data-e-type=\"container\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;sticky&quot;:&quot;top&quot;,&quot;sticky_offset_mobile&quot;:90,&quot;sticky_on&quot;:[&quot;widescreen&quot;,&quot;desktop&quot;,&quot;laptop&quot;,&quot;tablet_extra&quot;,&quot;tablet&quot;,&quot;mobile_extra&quot;,&quot;mobile&quot;],&quot;sticky_offset&quot;:0,&quot;sticky_effects_offset&quot;:0,&quot;sticky_anchor_link_offset&quot;:0}\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t<div class=\"elementor-element elementor-element-eaa5715 e-con-full elementor-hidden-desktop e-flex wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no e-con e-child\" data-id=\"eaa5715\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t<div class=\"elementor-element elementor-element-ecfad7d elementor-nav-menu__align-center elementor-nav-menu--stretch elementor-nav-menu--dropdown-tablet elementor-nav-menu__text-align-aside elementor-nav-menu--toggle elementor-nav-menu--burger elementor-widget elementor-widget-nav-menu\" data-id=\"ecfad7d\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;submenu_icon&quot;:{&quot;value&quot;:&quot;&lt;i class=\\&quot;\\&quot; aria-hidden=\\&quot;true\\&quot;&gt;&lt;\\\/i&gt;&quot;,&quot;library&quot;:&quot;&quot;},&quot;full_width&quot;:&quot;stretch&quot;,&quot;layout&quot;:&quot;horizontal&quot;,&quot;toggle&quot;:&quot;burger&quot;}\" data-widget_type=\"nav-menu.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t<nav aria-label=\"Menu\" class=\"elementor-nav-menu--main elementor-nav-menu__container elementor-nav-menu--layout-horizontal e--pointer-underline e--animation-fade\">\n\t\t\t\t<ul id=\"menu-1-ecfad7d\" class=\"elementor-nav-menu\"><li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22253\"><a href=\"\/pipeline\/#overview\" class=\"elementor-item elementor-item-anchor\">Vue d&rsquo;ensemble<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22254\"><a href=\"\/pipeline\/#xervyteg\" class=\"elementor-item elementor-item-anchor\">Xervyteg\u00ae (MaaT013)<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22255\"><a href=\"\/pipeline\/#maat033\" class=\"elementor-item elementor-item-anchor\">MaaT033<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22256\"><a href=\"\/pipeline\/#maat034\" class=\"elementor-item elementor-item-anchor\">MaaT034<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22257\"><a href=\"\/pipeline\/#maat03x\" class=\"elementor-item elementor-item-anchor\">MaaT03X<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22258\"><a href=\"\/pipeline\/#scientificpublications\" class=\"elementor-item elementor-item-anchor\">Publications scientifiques<\/a><\/li>\n<\/ul>\t\t\t<\/nav>\n\t\t\t\t\t<div class=\"elementor-menu-toggle\" role=\"button\" tabindex=\"0\" aria-label=\"Permuter le menu\" aria-expanded=\"false\">\n\t\t\t<span class=\"elementor-menu-toggle__icon--open\"><svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" fill=\"#000000\" width=\"800px\" height=\"800px\" viewBox=\"0 0 1024 1024\"><path d=\"M912 192H328c-4.4 0-8 3.6-8 8v56c0 4.4 3.6 8 8 8h584c4.4 0 8-3.6 8-8v-56c0-4.4-3.6-8-8-8zm0 284H328c-4.4 0-8 3.6-8 8v56c0 4.4 3.6 8 8 8h584c4.4 0 8-3.6 8-8v-56c0-4.4-3.6-8-8-8zm0 284H328c-4.4 0-8 3.6-8 8v56c0 4.4 3.6 8 8 8h584c4.4 0 8-3.6 8-8v-56c0-4.4-3.6-8-8-8zM104 228a56 56 0 1 0 112 0 56 56 0 1 0-112 0zm0 284a56 56 0 1 0 112 0 56 56 0 1 0-112 0zm0 284a56 56 0 1 0 112 0 56 56 0 1 0-112 0z\"><\/path><\/svg><\/span><i aria-hidden=\"true\" role=\"presentation\" class=\"elementor-menu-toggle__icon--close eicon-close\"><\/i>\t\t<\/div>\n\t\t\t\t\t<nav class=\"elementor-nav-menu--dropdown elementor-nav-menu__container\" aria-hidden=\"true\">\n\t\t\t\t<ul id=\"menu-2-ecfad7d\" class=\"elementor-nav-menu\"><li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22253\"><a href=\"\/pipeline\/#overview\" class=\"elementor-item elementor-item-anchor\" tabindex=\"-1\">Vue d&rsquo;ensemble<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22254\"><a href=\"\/pipeline\/#xervyteg\" class=\"elementor-item elementor-item-anchor\" tabindex=\"-1\">Xervyteg\u00ae (MaaT013)<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22255\"><a href=\"\/pipeline\/#maat033\" class=\"elementor-item elementor-item-anchor\" tabindex=\"-1\">MaaT033<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22256\"><a href=\"\/pipeline\/#maat034\" class=\"elementor-item elementor-item-anchor\" tabindex=\"-1\">MaaT034<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22257\"><a href=\"\/pipeline\/#maat03x\" class=\"elementor-item elementor-item-anchor\" tabindex=\"-1\">MaaT03X<\/a><\/li>\n<li class=\"menu-item menu-item-type-custom menu-item-object-custom menu-item-22258\"><a href=\"\/pipeline\/#scientificpublications\" class=\"elementor-item elementor-item-anchor\" tabindex=\"-1\">Publications scientifiques<\/a><\/li>\n<\/ul>\t\t\t<\/nav>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-1a3cfe3 elementor-icon-list--layout-inline elementor-align-center elementor-hidden-widescreen elementor-hidden-desktop elementor-hidden-laptop elementor-hidden-tablet_extra elementor-hidden-tablet elementor-hidden-mobile_extra elementor-hidden-mobile elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"1a3cfe3\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items elementor-inline-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Menu<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-7b3df24 elementor-hidden-tablet elementor-hidden-mobile_extra elementor-hidden-mobile elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"7b3df24\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;,&quot;sticky&quot;:&quot;top&quot;,&quot;sticky_offset&quot;:91,&quot;sticky_offset_mobile&quot;:100,&quot;sticky_on&quot;:[&quot;widescreen&quot;,&quot;desktop&quot;,&quot;laptop&quot;,&quot;tablet_extra&quot;,&quot;tablet&quot;,&quot;mobile_extra&quot;,&quot;mobile&quot;],&quot;sticky_effects_offset&quot;:0,&quot;sticky_anchor_link_offset&quot;:0}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-4e5ce51\" data-id=\"4e5ce51\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5ea06ad elementor-icon-list--layout-inline elementor-align-center elementor-list-item-link-full_width elementor-widget elementor-widget-icon-list\" data-id=\"5ea06ad\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"icon-list.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t<ul class=\"elementor-icon-list-items elementor-inline-items\">\n\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#overview\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Vue d'ensemble<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#xervyteg\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Xervyteg\u00ae (MaaT013)<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#maat033\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">MaaT033<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#maat034\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">MaaT034<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#maat03x\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">MaaT03X<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t\t\t<li class=\"elementor-icon-list-item elementor-inline-item\">\n\t\t\t\t\t\t\t\t\t\t\t<a href=\"#scientificpublications\">\n\n\t\t\t\t\t\t\t\t\t\t\t<span class=\"elementor-icon-list-text\">Publications scientifiques<\/span>\n\t\t\t\t\t\t\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t<\/li>\n\t\t\t\t\t\t<\/ul>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-3b8f10e elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"3b8f10e\" data-element_type=\"section\" data-e-type=\"section\" id=\"overview\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3317504\" data-id=\"3317504\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-82a92ae elementor-widget elementor-widget-heading\" data-id=\"82a92ae\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\"><strong>Le portefeuille de MaaT Pharma exploite deux approches :<\/strong><\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-c23aa23 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"c23aa23\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-6937563\" data-id=\"6937563\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3dcc81b elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"3dcc81b\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInLeft&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong><span style=\"color: #5bc0cc;\">Restaurer le microbiote en h\u00e9mato-oncologie :<\/span><\/strong><br \/>Les th\u00e9rapies de MaaT Pharma pour le traitement de la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGVH) et la pr\u00e9vention des complications de la greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) ont pour but de\u00a0<span style=\"color: #5bc0cc;\">restaurer les fonctions physiologiques d\u2019un\u00a0<a style=\"color: #5bc0cc;\" href=\"https:\/\/www.maatpharma.com\/fr\/microbiome-et-medecine\/\" target=\"_blank\" rel=\"noopener\">microbiote sain<\/a><\/span>\u00a0afin de corriger les effets de facteurs de stress comme les antibiotiques et les chimioth\u00e9rapies.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-f587681\" data-id=\"f587681\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5149ecc elementor-invisible elementor-widget elementor-widget-text-editor\" data-id=\"5149ecc\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInRight&quot;}\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong><span style=\"color: #5bc0cc;\">Restaurer et moduler le microbiote en immuno-oncologie :<\/span><\/strong><br \/>Les th\u00e9rapies de MaaT Pharma pour le traitement des tumeurs solides ont pour objectif de <span style=\"color: #5bc0cc;\">restaurer et moduler le microbiote<\/span> , dans le but d\u2019am\u00e9liorer la r\u00e9ponse aux inhibiteurs de points de contr\u00f4le immunitaires, traitements souvent incontournables dans ces indications.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-9d734f2 elementor-invisible elementor-widget elementor-widget-image\" data-id=\"9d734f2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"1704\" height=\"1080\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025.png\" class=\"attachment-full size-full wp-image-21686\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025.png 1704w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025-300x190.png 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025-1024x649.png 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025-768x487.png 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025-1536x974.png 1536w\" sizes=\"(max-width: 1704px) 100vw, 1704px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-b68c44d elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"b68c44d\" data-element_type=\"section\" data-e-type=\"section\" id=\"xervyteg\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-826e78c\" data-id=\"826e78c\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-061c812 elementor-widget-tablet__width-initial elementor-widget elementor-widget-heading\" data-id=\"061c812\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">\nXervyteg<sup style=\"font-size:20px\">\u00ae<\/sup> (MaaT013) : traiter la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGvH)<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-512f1f7\" data-id=\"512f1f7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4497e74 elementor-tablet-align-center elementor-widget elementor-widget-button\" data-id=\"4497e74\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.maatpharma.com\/fr\/?page_id=13885\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">Xervyteg\u00ae (MaaT013): R\u00e9sultats positifs de l'\u00e9tude pivotale \u2013 Plus d\u2019informations<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-574d4be elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"574d4be\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-976f4ab\" data-id=\"976f4ab\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-a4e39cc elementor-widget elementor-widget-heading\" data-id=\"a4e39cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Le besoin m\u00e9dical<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3e932b4 elementor-widget elementor-widget-text-editor\" data-id=\"3e932b4\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La\u00a0<a href=\"https:\/\/www.maatpharma.com\/fr\/patients-et-proches-de-patients\/#greffon\" target=\"_blank\" rel=\"noopener\"><span style=\"color: #5bc0cc;\">maladie aigu\u00eb du greffon contre l\u2019h\u00f4te (aGvH)<\/span><\/a>\u00a0survient chez les patients dans les 100 jours apr\u00e8s une greffe de cellules souches ou de moelle osseuse. Les cellules greff\u00e9es \u00ab\u00a0attaquent\u00a0\u00bb le receveur, provoquant une inflammation de la peau, du foie et\/ou du tractus gastro-intestinal et entra\u00eenant une morbidit\u00e9 et une mortalit\u00e9 \u00e9lev\u00e9es. L\u2019atteinte gastro-intestinale notamment est associ\u00e9e \u00e0 des complications graves telles que diarrh\u00e9es intenses, douleurs abdominales, h\u00e9morragies intestinales et mettant en jeu le pronostic vital du patient, avec un risque de mortalit\u00e9 accru, en raison des difficult\u00e9s li\u00e9es \u00e0 la prise en charge d\u2019une inflammation gastro-intestinale s\u00e9v\u00e8re et des risques associ\u00e9s d\u2019infection, de malnutrition et de d\u00e9faillance d\u2019organes.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-37ca340\" data-id=\"37ca340\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-56a81da elementor-invisible elementor-widget elementor-widget-image\" data-id=\"56a81da\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"800\" height=\"544\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/AdobeStock_235331642-1-1024x696.jpeg\" class=\"elementor-animation-bounce-in attachment-large size-large wp-image-15630\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/AdobeStock_235331642-1-1024x696.jpeg 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/AdobeStock_235331642-1-300x204.jpeg 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/AdobeStock_235331642-1-768x522.jpeg 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/AdobeStock_235331642-1-1536x1045.jpeg 1536w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2025\/06\/AdobeStock_235331642-1.jpeg 1588w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-08a8332 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"08a8332\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-faf3aa5\" data-id=\"faf3aa5\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b2bf1a9 elementor-widget elementor-widget-heading\" data-id=\"b2bf1a9\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation_tablet&quot;:&quot;slideInUp&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">30-50%<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-28262e1 elementor-widget elementor-widget-text-editor\" data-id=\"28262e1\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>des patients recevant une allo-GCSH d\u00e9veloppent une aGvH.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-5740faf\" data-id=\"5740faf\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-23324d2 elementor-invisible elementor-widget elementor-widget-heading\" data-id=\"23324d2\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation_tablet&quot;:&quot;slideInUp&quot;,&quot;_animation&quot;:&quot;fadeInDown&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">70-80%<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-14b04cc elementor-widget elementor-widget-text-editor\" data-id=\"14b04cc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Taux de mortalit\u00e9 constat\u00e9 apr\u00e8s 1 an chez les patients avec une aGvH cortico-r\u00e9sistante.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-inner-column elementor-element elementor-element-f1ab4c6\" data-id=\"f1ab4c6\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5604b18 elementor-widget elementor-widget-heading\" data-id=\"5604b18\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation_tablet&quot;:&quot;slideInUp&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Env.10000<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-854b524 elementor-widget elementor-widget-text-editor\" data-id=\"854b524\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>cas d\u2019aGvH en 2018 aux USA, UK, France, Allemagne, Italie, Espagne et Japon.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-d59c0b1 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"d59c0b1\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-inner-column elementor-element elementor-element-a176089\" data-id=\"a176089\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-7ada99e elementor-widget elementor-widget-html\" data-id=\"7ada99e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"html.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<script>\ndocument.addEventListener(\"DOMContentLoaded\", () => {\n\n  const headings = document.querySelectorAll(\".elementor-widget-heading h2\");\n\n  const animate = (el, start, end, during, finalText) => {\n    const duration = 1500;\n    const startTime = performance.now();\n\n    const step = (now) => {\n      const progress = Math.min((now - startTime) \/ duration, 1);\n      const value = Math.floor(start + (end - start) * progress);\n      el.textContent = during(value);\n\n      if (progress < 1) {\n        requestAnimationFrame(step);\n      } else {\n        el.textContent = finalText;\n      }\n    };\n\n    requestAnimationFrame(step);\n  };\n\n  const observer = new IntersectionObserver((entries, obs) => {\n    entries.forEach(entry => {\n      if (!entry.isIntersecting) return;\n\n      const el = entry.target;\n      const original = el.textContent.trim();\n\n      \/\/ \ud83d\udd39 30-50%\n      let match = original.match(\/^(\\d+)\\s*-\\s*(\\d+)%$\/);\n      if (match) {\n        animate(\n          el,\n          parseInt(match[1]),\n          parseInt(match[2]),\n          v => `${v}%`,\n          original\n        );\n        obs.unobserve(el);\n        return;\n      }\n\n      \/\/ \ud83d\udd39 ca.10,000\n      match = original.match(\/^ca\\.\\s*([\\d,]+)\/i);\n      if (match) {\n        const end = parseInt(match[1].replace(\/,\/g, \"\"));\n        animate(\n          el,\n          0,\n          end,\n          v => `ca.${v.toLocaleString()}`,\n          original\n        );\n        obs.unobserve(el);\n        return;\n      }\n\n    });\n  }, { threshold: 0.6 });\n\n  headings.forEach(h => observer.observe(h));\n});\n<\/script>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-8c9782e elementor-widget elementor-widget-text-editor\" data-id=\"8c9782e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLe traitement th\u00e9rapeutique standard de premi\u00e8re ligne pour traiter l\u2019aGvH est le recours aux st\u00e9ro\u00efdes. Si les patients ne r\u00e9pondent pas aux st\u00e9ro\u00efdes, ils sont consid\u00e9r\u00e9s comme r\u00e9sistants (SR) et d\u2019autres traitements peuvent \u00eatre administr\u00e9s comme le ruxolitinib. La perte de diversit\u00e9 du microbiote intestinal, li\u00e9e aux chimioth\u00e9rapies et antibioth\u00e9rapies intensives que les patients re\u00e7oivent avant la greffe de cellules souches, est pr\u00e9dictive de l\u2019incidence de la maladie du greffon contre l\u2019h\u00f4te et est \u00e9galement associ\u00e9e \u00e0 des taux de survie plus bas apr\u00e8s une allo-GCSH. <a href=\"#notes2\" name=\"_ftnref3\"><sup><span style=\"color: #283583;\"> 2,<\/span><\/sup><\/a><a href=\"#notes3\" name=\"_ftnref2\"><sup><span style=\"color: #283583;\">3, <\/span> <\/sup><\/a><a href=\"#notes3\" name=\"_ftnref3\"><sup><span style=\"color: #283583;\">4,<\/span><\/sup><\/a>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3b7cf53 elementor-widget elementor-widget-button\" data-id=\"3b7cf53\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"button.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"elementor-button-wrapper\">\n\t\t\t\t\t<a class=\"elementor-button elementor-button-link elementor-size-sm\" href=\"https:\/\/www.maatpharma.com\/fr\/patients-et-proches-de-patients\/#cancers\">\n\t\t\t\t\t\t<span class=\"elementor-button-content-wrapper\">\n\t\t\t\t\t\t\t\t\t<span class=\"elementor-button-text\">En apprendre plus sur les cancers du sang et l'aGvH<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-f38a916 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"f38a916\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c313243\" data-id=\"c313243\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-fbad772 elementor-widget elementor-widget-heading\" data-id=\"fbad772\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Restauration du microbiote avec Xervyteg\u00ae (MaaT013) : un produit \u00e0 densit\u00e9 maximale pour une implantation d\u2019esp\u00e8ces b\u00e9n\u00e9fiques rapide dans les situations d\u2019urgence<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-2503d3a elementor-widget elementor-widget-text-editor\" data-id=\"2503d3a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Xervyteg<sup>\u00ae<\/sup> (MaaT013) est une th\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet (MET) <span style=\"color: #5bc0cc;\">d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes<\/span> , qui contient le <span style=\"color: #5bc0cc;\">Butycore<sup>TM<\/sup><\/span> , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires. Xervyteg<sup>\u00ae<\/sup> (MaaT013) a obtenu la d\u00e9signation de m\u00e9dicament orphelin de la part de la FDA et de l\u2019EMA.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-266fec4 elementor-invisible elementor-widget elementor-widget-image\" data-id=\"266fec4\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInUp&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"1920\" height=\"944\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Xervyteg-presentation.png\" class=\"attachment-full size-full wp-image-23312\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Xervyteg-presentation.png 1920w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Xervyteg-presentation-300x148.png 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Xervyteg-presentation-1024x503.png 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Xervyteg-presentation-768x378.png 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Xervyteg-presentation-1536x755.png 1536w\" sizes=\"(max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-143245c elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"143245c\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-93ad512\" data-id=\"93ad512\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-3a303b1 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"3a303b1\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-e42457e\" data-id=\"e42457e\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b1bef6f elementor-widget elementor-widget-text-editor\" data-id=\"b1bef6f\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_wrapper\"><p data-start=\"56\" data-end=\"494\"><strong>Xervyteg\u00ae (MaaT013)<\/strong> est un candidat-m\u00e9dicament issu du microbiote actuellement en cours d\u2019examen r\u00e9glementaire en Europe pour le traitement de la\u00a0<strong data-start=\"213\" data-end=\"285\">maladie aigu\u00eb du greffon contre l\u2019h\u00f4te avec atteinte gastro-intestinale (GI-aGvH)<\/strong>. Ce traitement a \u00e9t\u00e9 \u00e9valu\u00e9 dans le cadre de l\u2019essai clinique pivotal ARES <span style=\"color: #333399;\">(<a style=\"color: #333399;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04769895\" data-wplink-edit=\"true\">NCT04769895<\/a>)<\/span>, le premier essai pivotal mondial portant sur une th\u00e9rapie issue du microbiote en h\u00e9mato-oncologie.<\/p><p data-start=\"496\" data-end=\"715\">L\u2019essai\u00a0<strong data-start=\"504\" data-end=\"512\">ARES<\/strong>\u00a0a recrut\u00e9 en Europe\u00a0<strong data-start=\"533\" data-end=\"581\">66 patients atteints de GI-aGvH r\u00e9fractaire<\/strong>\u00a0aux traitements de premi\u00e8re ligne par cortico\u00efdes et de deuxi\u00e8me ligne par\u00a0<strong data-start=\"657\" data-end=\"672\">ruxolitinib<\/strong>, les standards actuels de prise en charge.<\/p><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-6a3e8f0\" data-id=\"6a3e8f0\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-1b87a22 elementor-widget elementor-widget-heading\" data-id=\"1b87a22\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">300+<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-94a0888 elementor-widget elementor-widget-text-editor\" data-id=\"94a0888\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tpatients trait\u00e9s avec MaaT013 \u00e0 ce jour.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-c87fd1f elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"c87fd1f\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-wider\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-cbe03d1\" data-id=\"cbe03d1\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f0409fe elementor-widget elementor-widget-text-editor\" data-id=\"f0409fe\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong data-start=\"761\" data-end=\"788\">\u00c9tapes cliniques majeures :<\/strong><br data-start=\"788\" data-end=\"791\" \/>\u2013\u00a0<a href=\"https:\/\/www.maatpharma.com\/fr\/maat-pharma-annonce-le-traitement-dun-premier-patient-dans-letude-clinique-ares-de-phase-3-evaluant-maat013-dans-le-traitement-de-la-maladie-aigue-du-greffon-contre-l\/\">Premier patient trait\u00e9 dans l\u2019essai clinique pivotal ARES<\/a><br data-start=\"888\" data-end=\"891\" \/>\u2013\u00a0<a href=\"https:\/\/www.maatpharma.com\/fr\/26-octobre-2023-maat-pharma-annonce-les-conclusions-positives-du-dsmb-renforcant-la-confiance-dans-lessai-de-phase-3-en-cours-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-l\/\">Avis positif suite \u00e0 l\u2019\u00e9valuation du DSMB* pour l\u2019essai pivotal en cours,<\/a>\u00a0confirmant le profil de s\u00e9curit\u00e9<br data-start=\"974\" data-end=\"977\" \/>\u2013\u00a0<a href=\"https:\/\/www.maatpharma.com\/fr\/8-janvier-2025-maat-pharma-annonce-des-resultats-positifs-pour-letude-pivotale-de-phase-3-ares-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\">R\u00e9sultats principaux positifs de l\u2019\u00e9tude pivotale ARES \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l\u2019h\u00f4te,<\/a>\u00a0montrant une forte efficacit\u00e9 et un profil de s\u00e9curit\u00e9 favorable<br data-start=\"1168\" data-end=\"1171\" \/>\u2013\u00a0<a href=\"https:\/\/www.maatpharma.com\/fr\/18-mars-2025-maat-pharma-annonce-la-conclusion-positive-de-lexamen-final-du-dsmb-pour-lessai-clinique-pivotal-de-phase-3-evaluant-maat013-dans-la-maladie-aigue-du-greffon-contre-lhote\/\">Conclusion positive de l\u2019examen final du DSMB pour l\u2019essai clinique pivotal, <\/a>confirmant un profil b\u00e9n\u00e9fice-risque favorable<br data-start=\"1309\" data-end=\"1312\" \/>\u2013\u00a0<a href=\"https:\/\/www.maatpharma.com\/fr\/2-juin-2025-maat-pharma-progresse-vers-la-commercialisation-et-annonce-le-depot-dune-demande-dautorisation-de-mise-sur-le-marche-aupres-de-lagence-europeenne-des-medicaments-ema-pour\/\">Dossier de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) soumis \u00e0 l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA)<\/a>\u00a0en juin 2025 pour le traitement de la GI-aGvH<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-8ad6e96\" data-id=\"8ad6e96\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c2b4497 elementor-invisible elementor-widget elementor-widget-heading\" data-id=\"c2b4497\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;zoomIn&quot;}\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">Si approuv\u00e9, Xervyteg\u00ae (MaaT013) a le potentiel de devenir le premier m\u00e9dicament issu du microbiote approuv\u00e9 par l\u2019EMA, et le premier au niveau mondial <br> dans une indication en h\u00e9matologie.<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-c45d370 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"c45d370\" data-element_type=\"section\" data-e-type=\"section\" id=\"maat033\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-e71fbf3\" data-id=\"e71fbf3\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-5cf56db elementor-widget elementor-widget-heading\" data-id=\"5cf56db\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">MaaT033 : la capsule de microbiote \u00e0 \u00e9cosyst\u00e8me complet, en forme orale, pour des traitements adjuvants<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-e62bcf7 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"e62bcf7\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-c91d134\" data-id=\"c91d134\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-f000261 elementor-widget elementor-widget-heading\" data-id=\"f000261\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Le besoin m\u00e9dical<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5eb39ef elementor-widget elementor-widget-text-editor\" data-id=\"5eb39ef\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>La transplantation de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) est une proc\u00e9dure susceptible de sauver la vie de patients souffrant de cancers du sang comme la leuc\u00e9mie aig\u00fce my\u00e9lo\u00efde. Malheureusement, elle peut \u00e9galement \u00eatre associ\u00e9e \u00e0 des complications graves, comme des infections, la maladie du greffon contre l\u2019h\u00f4te, ou la neutrop\u00e9nie, qui contribuent \u00e0 une mortalit\u00e9 de l\u2019ordre de 34%<sup>6<\/sup>, un an apr\u00e8s la proc\u00e9dure chez les patients de plus de 50 ans.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-26cb90b\" data-id=\"26cb90b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-44dda40 elementor-widget elementor-widget-heading\" data-id=\"44dda40\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h4 class=\"elementor-heading-title elementor-size-default\">Env.20000<\/h4>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-cdd17b5 elementor-widget elementor-widget-text-editor\" data-id=\"cdd17b5\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tpatients re\u00e7oivent une premi\u00e8re allo-GCSH <br>chaque ann\u00e9e aux USA, UK, France, Allemagne, <br>Italie, Espagne et Japon.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-62d4193 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"62d4193\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-ff6dc47\" data-id=\"ff6dc47\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4d821ab elementor-widget elementor-widget-heading\" data-id=\"4d821ab\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">\nMaaT033 pour am\u00e9liorer la survie des patients recevant des allo-GSCH<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b29de90 elementor-widget elementor-widget-text-editor\" data-id=\"b29de90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLa perte de diversit\u00e9 du microbiote intestinal li\u00e9e \u00e0 la chimioth\u00e9rapie et aux antibiotiques utilis\u00e9s en amont de l\u2019allo-GSCH est pr\u00e9dictive de la mortalit\u00e9 des patients soumis \u00e0 la proc\u00e9dure, ainsi que du risque de d\u00e9velopper une maladie du greffon contre l\u2019h\u00f4te et des infections.<a href=\"#_ftn3\" name=\"_ftnref3\"><sup>2 3<\/sup><\/a><a href=\"#_ftn4\" name=\"_ftnref4\"><sup> 4<\/sup><\/a><a href=\"#_ftn5\" name=\"_ftnref5\"><sup> 7<\/sup><\/a>\nMaaT033 est une th\u00e9rapie issue du microbiote (MET) sous<span style=\"color: #5bc0cc;\"> forme orale, d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes<\/span> , qui contient le <span style=\"color: #5bc0cc;\">Butycore<sup>TM<\/sup><\/span> , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-01cfe1e elementor-invisible elementor-widget elementor-widget-image\" data-id=\"01cfe1e\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInUp&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"4132\" height=\"1831\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/FR-MaaT033-1.png\" class=\"attachment-full size-full wp-image-21688\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/FR-MaaT033-1.png 4132w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/FR-MaaT033-1-300x133.png 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/FR-MaaT033-1-1024x454.png 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/FR-MaaT033-1-768x340.png 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/FR-MaaT033-1-1536x681.png 1536w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/FR-MaaT033-1-2048x908.png 2048w\" sizes=\"(max-width: 4132px) 100vw, 4132px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c32b704 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"c32b704\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Le mode d\u2019action suppos\u00e9 de MaaT033 est immuno-modulateur :<\/strong><\/p><ul style=\"list-style-type: disc;\"><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><span style=\"color: #5bc0cc;\">Restauration de la richesse et de la diversit\u00e9 microbiennes<\/span> et production d\u2019acides gras \u00e0 cha\u00eene courte immunomodulateurs, qui r\u00e9gulent positivement les cellules TReg, et participent ainsi \u00e0 la restauration de l\u2019hom\u00e9ostase immunitaires.<\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><span style=\"color: #5bc0cc;\">Restauration de la barri\u00e8re intestinale<\/span>, qui joue un r\u00f4le cl\u00e9 dans la pr\u00e9vention des infections et en particulier celles li\u00e9es aux bact\u00e9ries multi-r\u00e9sistantes (MDRB)<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f5621ac elementor-widget elementor-widget-heading\" data-id=\"f5621ac\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Statut de d\u00e9veloppement de MaaT033<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-f4ce4a0 elementor-widget elementor-widget-text-editor\" data-id=\"f4ce4a0\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p><strong>Des r\u00e9sultats positifs de Phase 1b<\/strong><br \/>En juin 2022, MaaT Pharma a annonc\u00e9 des r\u00e9sultats positifs pour MaaT033 dans un essai clinique de<span style=\"color: #5bc0cc;\">\u00a0<a style=\"color: #5bc0cc;\" href=\"https:\/\/www.maatpharma.com\/fr\/maat-pharma-confirme-les-resultats-positifs-de-letude-cimon-de-phase-1b-evaluant-maat033-chez-des-patients-avec-un-cancer-du-sang\/\">Phase 1 (CIMON)<\/a><\/span>\u00a0aupr\u00e8s de patients atteints de leuc\u00e9mie my\u00e9lo\u00efde aigu\u00eb, \u00e0 savoir\u00a0<span style=\"color: #5bc0cc;\">une bonne implantation des esp\u00e8ces bact\u00e9riennes b\u00e9n\u00e9fiques<\/span>, qui se maintient dans le temps, associ\u00e9e \u00e0\u00a0<span style=\"color: #5bc0cc;\">un profil de s\u00e9curit\u00e9 satisfaisant<\/span>.<\/p><p><strong>Plus d\u2019informations :<\/strong><\/p><ul style=\"list-style-type: disc;\"><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i>Clinical trial :\u00a0<span style=\"color: #33cccc;\"><a style=\"color: #33cccc;\" href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04150393\">NCT04150393<\/a><\/span><\/li><li><span style=\"color: #33cccc;\"><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a style=\"color: #33cccc;\" href=\"https:\/\/www.maatpharma.com\/fr\/maat-pharma-confirme-les-resultats-positifs-de-letude-cimon-de-phase-1b-evaluant-maat033-chez-des-patients-avec-un-cancer-du-sang\/?preview_id=7828&amp;preview_nonce=740fbc86f1&amp;post_format=standard&amp;_thumbnail_id=7120&amp;preview=true\">Communiqu\u00e9 de presse R\u00e9sultats cliniques CIMON Phase 1b<\/a><\/span><\/li><li><span style=\"color: #33cccc;\"><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a style=\"color: #33cccc;\" href=\"https:\/\/www.maatpharma.com\/fr\/restoration-of-gut-microbiota-diversity-with-oral-pooled-fecal-microbiotherapy-in-acute-myeloid-leukemia-patients-after-intensive-chemotherapy-the-phase-1b-cimon-trial\/\">Voir le poster d\u00e9taillant les r\u00e9sultats complets de CIMON pr\u00e9sent\u00e9s \u00e0 l\u2019ASH 2022<\/a><\/span><\/li><\/ul><p>\u00a0<\/p><p><strong>Essai clinique de Phase 2b en cours<\/strong><br \/>En<a href=\"\/fr\/6-novembre-2023-maat-pharma-annonce-le-traitement-dun-premier-patient-dans-lessai-clinique-randomise-de-phase-2b-evaluant-maat033-chez-des-patients-recevant-une-allo-gcsh\/\">\u00a0<span style=\"color: #5bc0cc;\">novembre 2023<\/span><\/a>, MaaT Pharma a annonc\u00e9 le traitement du premier patient dans le cadre de son essai de Phase 2b (PHOEBUS) \u00e9valuant l\u2019efficacit\u00e9 de MaaT033 dans l\u2019am\u00e9lioration de la survie globale \u00e0 12 mois pour les patients atteints d\u2019un cancer du sang ayant re\u00e7u une allo-GCSH. L\u2019essai, une \u00e9tude internationale, multicentrique, randomis\u00e9e, en double aveugle et contr\u00f4l\u00e9e par placebo (<a href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05762211?term=PHOEBUS&amp;draw=2&amp;rank=1\"><span style=\"color: #5bc0cc;\">NCT05762211<\/span><\/a>), sera men\u00e9 dans 59 sites d\u2019investigation et devrait inclure 388 patients. Il s\u2019agit, \u00e0 ce jour, du plus grand essai contr\u00f4l\u00e9 randomis\u00e9 \u00e9valuant une th\u00e9rapie \u00e0 base de microbiote en oncologie.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6ffbe71 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"6ffbe71\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-c71a794\" data-id=\"c71a794\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-4507cdd elementor-widget elementor-widget-heading\" data-id=\"4507cdd\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">MaaT033 : restaurer la diversit\u00e9 et la richesse du microbiote intestinal chez les patients atteints de SLA<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-95f1f02 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"95f1f02\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-7831c35\" data-id=\"7831c35\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-b8cdcea elementor-widget elementor-widget-heading\" data-id=\"b8cdcea\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Le besoin m\u00e9dical<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-6571234 elementor-widget elementor-widget-text-editor\" data-id=\"6571234\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Des \u00e9tudes r\u00e9centes mettent de plus en plus en exergue le r\u00f4le du microbiote intestinal, en \u00e9tablissant notamment un lien entre des alt\u00e9rations et des maladies telles que la scl\u00e9rose lat\u00e9rale amyotrophique (SLA<span style=\"color: #5bc0cc;\"><a style=\"color: #5bc0cc;\" href=\"\/fr\/pipeline\/#_ftn8\" name=\"_ftnref8\">[8]<\/a><\/span>). Le lien entre le microbiote intestinal et la SLA a \u00e9t\u00e9 document\u00e9, dans un premier temps, au travers de donn\u00e9es pr\u00e9cliniques, puis d\u2019observations cliniques d\u00e9montrant le r\u00f4le modificateur jou\u00e9 par le microbiote intestinal dans la maladie. \u00c0 ce jour, il n\u2019existe aucun traitement efficace contre la SLA, une maladie qui\u00a0conduit au d\u00e9c\u00e8s en moyenne dans les 3\u00a0\u00e0 5\u00a0ans apr\u00e8s le diagnostic<a href=\"\/fr\/pipeline\/#_ftn9\" name=\"_ftnref9\"><span style=\"color: #5bc0cc;\">[9]<\/span><\/a>.<\/p><p>Depuis sa cr\u00e9ation, MaaT Pharma s\u2019est engag\u00e9e \u00e0 r\u00e9tablir la symbiose du microbiote dans les maladies graves avec des besoins m\u00e9dicaux non-satisfaits importants. De plus en plus d\u2019\u00e9tudes sugg\u00e8rent que les patients atteints de SLA pr\u00e9sentent une inflammation au niveau de l\u2019intestin et des alt\u00e9rations de la composition des microbes intestinaux, avec des niveaux de bact\u00e9ries b\u00e9n\u00e9fiques r\u00e9duits.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-5cfdeb0\" data-id=\"5cfdeb0\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-be67e90 elementor-widget elementor-widget-heading\" data-id=\"be67e90\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">env.60000<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e2c3400 elementor-widget elementor-widget-text-editor\" data-id=\"e2c3400\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>patients aux \u00c9tats-Unis et en Europe d&rsquo;ici 2040<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6188b17 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"6188b17\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3a8a2c3\" data-id=\"3a8a2c3\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-c2e657b elementor-widget elementor-widget-heading\" data-id=\"c2e657b\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">MaaT033 pour ralentir la progression de la maladie de Charcot (SLA)<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-59fd030 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"59fd030\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>MaaT Pharma a ainsi d\u00e9cid\u00e9 d\u2019\u00e9tendre sa recherche scientifique \u00e0 la SLA, ce qui pourrait ouvrir la voie pour une approche d\u00e9di\u00e9e pour plusieurs\u00a0<span style=\"color: #5bc0cc;\">maladies neurod\u00e9g\u00e9n\u00e9ratives<\/span>. La Soci\u00e9t\u00e9 s\u2019appuie sur le\u00a0<span style=\"color: #5bc0cc;\">bon profil de s\u00e9curit\u00e9 de ses produits MET natifs (MaaT033\/MaaT013), mais \u00e9galement sur les modes d\u2019actions inh\u00e9rents aux produits, \u00e0 savoir la modulation immunitaire\/les propri\u00e9t\u00e9s anti-inflammatoires et leur r\u00f4le central pour maintenir l\u2019hom\u00e9ostasie.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-45f0777 elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"45f0777\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-f4f70b0\" data-id=\"f4f70b0\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-01c0b64 elementor-widget elementor-widget-text-editor\" data-id=\"01c0b64\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Cette extension du portefeuille \u00e0 une nouvelle indication souligne le potentiel de MaaT033 \u00e0 \u00eatre utilis\u00e9 en tant que th\u00e9rapie en utilisation seule ou adjuvante dans des situations\u00a0 aigu\u00ebs ou chroniques.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-94623b4\" data-id=\"94623b4\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-01be6ae elementor-invisible elementor-widget elementor-widget-image\" data-id=\"01be6ae\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInLeft&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"517\" height=\"211\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS.png\" class=\"attachment-full size-full wp-image-21682\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS.png 517w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS-300x122.png 300w\" sizes=\"(max-width: 517px) 100vw, 517px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-c163626 elementor-widget elementor-widget-text-editor\" data-id=\"c163626\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li>&#8211; Jusqu\u2019\u00e0 15 patients dans une \u00e9tude pilote ouverte de Phase 1b en France<\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i>&#8211; Objectifs cl\u00e9s de l\u2019\u00e9tude : \u00e9valuer la s\u00e9curit\u00e9 et la tol\u00e9rabilit\u00e9 de MaaT033 ainsi que l\u2019\u00e9volution de la composition du microbiote intestinal<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d0468cb elementor-invisible elementor-widget elementor-widget-image\" data-id=\"d0468cb\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;fadeInDown&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"80\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS-2-1024x102.png\" class=\"attachment-large size-large wp-image-21680\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS-2-1024x102.png 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS-2-300x30.png 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS-2-768x76.png 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_ALS-2.png 1396w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-396f67a elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"396f67a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>This pipeline expansion to a new indication demonstrates the strong potential of MaaT033 to be used in acute or in chronic conditions as a standalone, adjunctive therapy.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e0dae74 elementor-hidden-desktop elementor-hidden-tablet elementor-hidden-mobile elementor-widget elementor-widget-text-editor\" data-id=\"e0dae74\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>ClinicalTrials.gov Identifier: <a style=\"color: #5bc0cc !important;\" href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05889572?term=MAAT033+ALS&amp;draw=2&amp;rank=1\">NCT05889572<\/a><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-6c980c9 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"6c980c9\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;background_background&quot;:&quot;classic&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-f9c357b\" data-id=\"f9c357b\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2a48374 elementor-widget elementor-widget-elementskit-accordion\" data-id=\"2a48374\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"elementskit-accordion.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<div class=\"ekit-wid-con\" >\n        <div class=\"elementskit-accordion accoedion-primary\" id=\"accordion-69e2746f92330\">\n\n            \n                <div class=\"elementskit-card \">\n                    <div class=\"elementskit-card-header\" id=\"primaryHeading-0-2a48374\">\n                        <a href=\"#collapse-505db0d69e2746f92330\" class=\"ekit-accordion--toggler elementskit-btn-link collapsed\" data-ekit-toggle=\"collapse\" data-target=\"#Collapse-505db0d69e2746f92330\" aria-expanded=\"false\" aria-controls=\"Collapse-505db0d69e2746f92330\">\n                            \n                            <span class=\"ekit-accordion-title\">Sources<\/span>\n\n                            \n                                <div class=\"ekit_accordion_icon_group\">\n                                    <div class=\"ekit_accordion_normal_icon\">\n                                        <!-- Normal Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\"lnr lnr-plus-circle\"><\/i>                                    <\/div>\n\n                                    <div class=\"ekit_accordion_active_icon\">\n                                        <!-- Active Icon -->\n\t\t\t\t\t\t\t\t\t\t<i class=\" icon_minus_alt2\"><\/i>                                    <\/div>\n                                <\/div>\n\n                            \n                                                    <\/a>\n                    <\/div>\n\n                    <div id=\"Collapse-505db0d69e2746f92330\" class=\" collapse\" aria-labelledby=\"primaryHeading-0-2a48374\" data-parent=\"#accordion-69e2746f92330\">\n\n                        <div class=\"elementskit-card-body ekit-accordion--content\">\n                            <p><em><span style=\"color: #5bc0cc\"><a style=\"color: #5bc0cc\" href=\"\/fr\/pipeline\/#_ftnref2\">1<\/a>\u00a0<\/span>Castilla-Llorente. C, et al. Prognostic factors and outcomes of severe gastrointestinal GVHD after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2014 49(7):966-71. doi:10.1038\/bmt.2014.69<\/em><br \/><em><a><\/a>2\u00a0Peled JU, et al. Role of the intestinal mucosa in acute gastrointestinal GVHD. Blood. 2016 128(20):2395-2402. doi: 10.1182\/blood-2016-06-716738.<\/em><br \/><em>Staffas A, et al. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease. Blood. 2017 129(8):927-933. doi: 10.1182\/blood-2016-09-691394. Erratum in: Blood. 2017 Apr 13;129(15):2204<\/em><br \/><em>Mathewson ND, et al. Gut microbiome-derived metabolites modulate intestinal epithelial cell damage and mitigate graft-versus-host disease. Nat Immunol. 2016 505-513. doi: 10.1038\/ni.3400. Epub 2016 Mar 21. Erratum in: Nat Immunol. 2016 Sep 20;17 (10 ):1235.<\/em><br \/><em><a><\/a>3\u00a0 Taur Y, et al. The effects of intestinal tract bacterial diversity on mortality following allogeneic hematopoietic stem cell transplantation. Blood. 2014 124(7):1174-82. doi:10.1182\/blood-2014-02-554725.<\/em><br \/><em>Jenq RR, et al. Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. J Exp Med. 2012 903-11. doi: 10.1084\/jem.20112408.<\/em><br \/><em><span style=\"color: #5bc0cc\"><a style=\"color: #5bc0cc\" href=\"\/fr\/pipeline\/#_ftnref5\">4<\/a><\/span>\u00a0Jenq RR, et al. Intestinal Blautia Is Associated with Reduced Death from Graft-versus-Host Disease. Biol Blood Marrow Transplant. 2015 1373-83. doi:10.1016\/j.bbmt.2015.04.016.<\/em><br \/><em>Peled JU, et al. Intestinal Microbiota and Relapse After Hematopoietic-Cell Transplantation. J Clin Oncol. 2017 1650-1659. doi:10.1200\/JCO.2016.70.3348<\/em><br \/><em><a href=\"https:\/\/www.maatpharma.com\/fr\/pipeline\/#_ftnref1\">5<\/a>\u00a0 Global Data GVHD Epidemiology Report, Jan 2020.<\/em><br \/><em><a href=\"https:\/\/www.maatpharma.com\/fr\/pipeline\/#_ftnref2\">6<\/a>\u00a0EBMT data 2021<\/em><br \/><em><a href=\"https:\/\/www.maatpharma.com\/fr\/pipeline\/#_ftnref3\">7<\/a>\u00a0Malard, F., Vekhoff, A., Lapusan, S. et al. Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients. Nat Commun 12, 3084 (2021). https:\/\/doi.org\/10.1038\/s41467-021-23376-6<\/em><br \/><a href=\"https:\/\/www.maatpharma.com\/fr\/pipeline\/#_ftnref8\"><em>[8]<\/em><\/a><em>\u00a0Rowin et al., 2017; Nicholson et al, 2021; Blacher et al, 2019, Mazzini et al, 2020<\/em><br \/><a href=\"https:\/\/www.maatpharma.com\/fr\/pipeline\/#_ftnref93\"><em>[9]<\/em><\/a><em>\u00a0https:\/\/tousensellescontrelasla.fr\/la-sla-cest-quoi\/<\/em><br \/><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0952791525001256\" target=\"_blank\" rel=\"noopener\"><em>[10]<\/em><\/a><em>\u00a0Yishan Ye, Wenjing Hao, Florent Malard, Mohamad Mohty, Emerging novel therapies for steroid-refractory acute graft-versus-host disease: recent advances and future directions, Current Opinion in Immunology, Volume 96, 2025, https:\/\/doi.org\/10.1016\/j.coi.2025.102649.<\/em><br \/><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/pii\/S0952791525001529\" target=\"_blank\" rel=\"noopener\"><em>[11]<\/em><\/a><em>\u00a0Emmanuelle Godefroy, Fr\u00e9d\u00e9ric Altare, Deciphering and harnessing gut microbiota\u2013associated immune regulation in acute graft-versus-host disease, Current Opinion in Immunology, Volume 97, 2025, https:\/\/doi.org\/10.1016\/j.coi.2025.102676.<\/em><\/p>                        <\/div>\n\n                    <\/div>\n\n                <\/div><!-- .elementskit-card END -->\n\n                                        <\/div>\n    <\/div>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-8d12cb8 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"8d12cb8\" data-element_type=\"section\" data-e-type=\"section\" id=\"maat03x\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b83e098\" data-id=\"b83e098\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-36f9256 elementor-widget elementor-widget-heading\" data-id=\"36f9256\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">MaaT03X pour am\u00e9liorer les traitements contre les cancers<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<section class=\"elementor-section elementor-inner-section elementor-element elementor-element-59afa2f elementor-section-full_width elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"59afa2f\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-9694102\" data-id=\"9694102\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-3ce757c elementor-widget elementor-widget-heading\" data-id=\"3ce757c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Le besoin m\u00e9dical<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b717694 elementor-widget elementor-widget-text-editor\" data-id=\"b717694\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLes<span style=\"color: #5bc0cc;\">\u00a0Inhibiteurs de points de Contr\u00f4le Immunitaires (ICI)<\/span>\u00a0se sont \u00e9tablis comme une option th\u00e9rapeutique de choix pour le traitement des tumeurs solides. Ils ont notamment am\u00e9lior\u00e9 les chances de survie des patients dans plus d\u2019une quinzaine d\u2019indications \u00e0 ce jour. Cependant, certains patients ne r\u00e9pondent pas au traitement par ICIs. Dans certaines indications, il a \u00e9t\u00e9 sugg\u00e9r\u00e9 que le microbiote intestinal pourrait jouer un r\u00f4le dans la r\u00e9ponse aux ICI.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-50 elementor-inner-column elementor-element elementor-element-e3720f7\" data-id=\"e3720f7\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-d907921 elementor-widget elementor-widget-heading\" data-id=\"d907921\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">40-80%\n<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-5f6db4e elementor-widget elementor-widget-text-editor\" data-id=\"5f6db4e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tdes patients ne r\u00e9pondent pas aux ICI, selon <br>l\u2019indication.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<div class=\"elementor-element elementor-element-f2dd0a3 elementor-invisible elementor-widget elementor-widget-image\" data-id=\"f2dd0a3\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInDown&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"384\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/maat3X-disco-1-scaled-1-1024x491.jpg\" class=\"attachment-large size-large wp-image-21786\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/maat3X-disco-1-scaled-1-1024x491.jpg 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/maat3X-disco-1-scaled-1-300x144.jpg 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/maat3X-disco-1-scaled-1-768x368.jpg 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/maat3X-disco-1-scaled-1-1536x736.jpg 1536w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/maat3X-disco-1-scaled-1.jpg 1920w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0378c84 elementor-widget elementor-widget-text-editor\" data-id=\"0378c84\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>En utilisant notre plateforme d\u2019analyse gutPrint, nous d\u00e9veloppons <span style=\"color: #5bc0cc;\">des\u00a0produits d\u00e9di\u00e9s pour chaque indication, qui combinent haute richesse et haute diversit\u00e9 bact\u00e9rienne avec des r\u00e9seaux fonctionnels bact\u00e9riens sp\u00e9cifiques<\/span>, dans le but d\u2019am\u00e9liorer le taux de r\u00e9ponse aux ICI. Chaque produit est con\u00e7u sur la base d\u2019une analyse, <a style=\"color: #5bc0cc;\">effectu\u00e9e par IA<\/a>, de donn\u00e9es issues de patients et de donneurs sains, et d\u00e9velopp\u00e9 via notre\u00a0<a style=\"color: #5bc0cc;\" href=\"https:\/\/www.maatpharma.com\/fr\/?page_id=4053\">technologie unique et innovante de co-culture<\/a>, qui permet de r\u00e9pliquer et d\u2019exploiter, \u00e0 l\u2019\u00e9chelle industrielle, la richesse et la diversit\u00e9 de microbiote natifs. Cela nous permet d\u2019adapter le produit \u00e0 une composition sp\u00e9cifique pour une indication th\u00e9rapeutique d\u00e9di\u00e9e.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-96464e1 elementor-widget elementor-widget-heading\" data-id=\"96464e1\" data-element_type=\"widget\" data-e-type=\"widget\" id=\"maat034\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">MaaT034 \u2013 une th\u00e9rapie issue de microbiote synth\u00e9tique innovant, ind\u00e9pendant des donneurs et dot\u00e9 d\u2019un \u00e9cosyst\u00e8me complet, pour optimiser le traitement par inhibiteurs de points de contr\u00f4le immunitaire (ICI).<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-87a41dc elementor-widget elementor-widget-text-editor\" data-id=\"87a41dc\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<div class=\"wpb_text_column wpb_content_element \"><div class=\"wpb_wrapper\"><p class=\"x_MsoNormal\">MaaT034, produit de co-culture \u00ab\u00a0first-in-class\u00a0\u00bb, vise \u00e0 optimiser les fonctions du microbiome intestinal avant et pendant l\u2019immunoth\u00e9rapie dans les principales indications oncologiques, et \u00e0 devenir une th\u00e9rapie (n\u00e9o)-adjuvante \u00e0 travers les th\u00e9rapies ICI, conduisant \u00e0 une meilleure survie chez les patients atteints de cancer. L\u2019objectif de MaaT Pharma est de d\u00e9velopper MaaT034 en tant que th\u00e9rapie en combinaison avec les ICI (c.-\u00e0-d. administration avant et en combinaison avec les ICI quel que soit le type de cancer) conduisant \u00e0 de meilleurs r\u00e9sultats cliniques et \u00e0 une incidence plus faible de complications que l\u2019utilisation des ICI seuls.<\/p><p class=\"x_MsoNormal\">Pour y parvenir, MaaT Pharma capitalisera sur les produits MET-N : un essai promu par les investigateurs est d\u00e9j\u00e0 en cours dans les tumeurs solides avec l\u2019essai PICASSO (m\u00e9lanome m\u00e9tastatique, avec Xervyteg<sup>\u00ae<\/sup> \u2013 MaaT013) pour \u00e9valuer la s\u00e9curit\u00e9 des produits MET-N en combinaison avec l\u2019ICI et recueillir des donn\u00e9es pr\u00e9liminaires d\u2019efficacit\u00e9 \u00e9valuant l\u2019impact des produits MET sur le syst\u00e8me immunitaire et les r\u00e9ponses anti-tumorales.<\/p><\/div><\/div>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-3c8db2c elementor-invisible elementor-widget elementor-widget-image\" data-id=\"3c8db2c\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInUp&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"329\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_MaaT034-1-1024x421.jpg\" class=\"attachment-large size-large wp-image-21678\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_MaaT034-1-1024x421.jpg 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_MaaT034-1-300x123.jpg 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_MaaT034-1-768x316.jpg 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline_MaaT034-1.jpg 1280w\" sizes=\"(max-width: 800px) 100vw, 800px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-4c6ed8a elementor-widget elementor-widget-heading\" data-id=\"4c6ed8a\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">MaaT03X : th\u00e9rapies issues de microbiotes synth\u00e9tiques super-comp\u00e9tents produites sur-mesure via IA et sp\u00e9cifiques \u00e0 une indication<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d0ed450 elementor-widget__width-initial elementor-widget elementor-widget-text-editor\" data-id=\"d0ed450\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>MaaT03X est une th\u00e9rapie issue de microbiote \u00e0 \u00e9cosyst\u00e8me complet super-comp\u00e9tent d\u00e9velopp\u00e9e par co-culture adapt\u00e9 \u00e0 des indications sp\u00e9cifiques. Gr\u00e2ce \u00e0 la collecte de donn\u00e9es aupr\u00e8s de patients, de donneurs sains et de la litt\u00e9rature, ainsi que de donn\u00e9es recueillies au cours du d\u00e9veloppement de MaaT034 (\u00e9chantillons f\u00e9caux et biologiques), MaaT Pharma alimente continuellement la plateforme d\u2019IA gutPrint, pour d\u00e9velopper des m\u00e9dicaments-microbiote de nouvelle g\u00e9n\u00e9ration<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-bc32bef elementor-invisible elementor-widget elementor-widget-image\" data-id=\"bc32bef\" data-element_type=\"widget\" data-e-type=\"widget\" data-settings=\"{&quot;_animation&quot;:&quot;slideInUp&quot;}\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"816\" src=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/MaaT03X-fr-pipeline.png-scaled-1.jpg\" class=\"attachment-full size-full wp-image-21684\" alt=\"\" srcset=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/MaaT03X-fr-pipeline.png-scaled-1.jpg 1920w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/MaaT03X-fr-pipeline.png-scaled-1-300x128.jpg 300w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/MaaT03X-fr-pipeline.png-scaled-1-1024x435.jpg 1024w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/MaaT03X-fr-pipeline.png-scaled-1-768x326.jpg 768w, https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/MaaT03X-fr-pipeline.png-scaled-1-1536x653.jpg 1536w\" sizes=\"(max-width: 1920px) 100vw, 1920px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-0f715e2 elementor-section-boxed elementor-section-height-default elementor-section-height-default wpr-particle-no wpr-jarallax-no wpr-parallax-no wpr-sticky-section-no wpr-equal-height-no\" data-id=\"0f715e2\" data-element_type=\"section\" data-e-type=\"section\" id=\"scientificpublications\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-6b0aa89\" data-id=\"6b0aa89\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-ac13978 elementor-widget elementor-widget-heading\" data-id=\"ac13978\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">Publications scientifiques<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-d69cd9e elementor-widget elementor-widget-heading\" data-id=\"d69cd9e\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Articles dans des Revues \u00e0 Comit\u00e9 de Lecture<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b166d57 elementor-widget elementor-widget-text-editor\" data-id=\"b166d57\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><a href=\"https:\/\/www.nature.com\/articles\/s41409-026-02825-0\">Clausen, J., P\u00e9rez Sim\u00f3n, J.A., Carr\u00e9, M.\u00a0<i>et al.<\/i> (2026). linical outcomes of third-line therapy for aGvHD with gastrointestinal involvement after steroids and ruxolitinib failure.\u00a0<i>Bone Marrow Transplant<\/i><\/a><\/li><li><a href=\"https:\/\/www.mdpi.com\/2076-2607\/12\/11\/2256\">Biennier S.<em>\u00a0et al<\/em>\u00a0(2024). Narrative Review: Advancing Dysbiosis Treatment in Onco-Hematology with Microbiome-Based Therapeutic Approach.\u00a0<em>Microorganisms<\/em><\/a><\/li><li><a href=\"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03487-2#citeas\">Laperrousaz B.\u00a0<em>et al<\/em>\u00a0(2024). Safety comparison of single-donor and pooled fecal microbiota transfer product preparation in ulcerative colitis: systematic review and meta-analysis.\u00a0<em>BMC Gastroenterology<\/em><\/a><\/li><li><a href=\"https:\/\/journals.asm.org\/doi\/10.1128\/aem.00016-24\"><span style=\"color: #283583;\">Reygner J.<em> et al<\/em> (2024). Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models. Applied and Environmental Microbiology- ASM Journals<\/span><\/a><\/li><li><a href=\"https:\/\/www.thelancet.com\/journals\/eclinm\/article\/PIIS2589-5370(23)00288-2\/fulltext\">Malard F\u00a0<em>et al<\/em>. (2023).\u00a0Pooled allogeneic faecal microbiota MaaT013 for steroid-resistant gastrointestinal acute graft-versus-host disease: a single-arm, multicentre phase 2 trial.\u00a0<em>eClinicalMedicine<\/em><\/a><\/li><li><a href=\"https:\/\/www.nature.com\/articles\/s41467-021-23376-6\" target=\"_blank\" rel=\"noopener\">Malard F.\u00a0<em>et al<\/em>. (2021). Restoration of gut microbiota diversity with autologous fecal microbiota transfer in acute myeloid leukemia patients.\u00a0<em>Nature communications<\/em>.\u00a0<\/a><\/li><li><a href=\"https:\/\/www.nature.com\/articles\/s41409-018-0254-x\">Malard F.\u00a0<em>et al.<\/em>\u00a0(2018). High gastrointestinal microbial diversity and clinical outcome in graft-versus-host disease patients.\u00a0<em>Bone Marrow Transplantation<\/em>.<\/a><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-832fd31 elementor-widget elementor-widget-heading\" data-id=\"832fd31\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Communications \u00ab Posters \u00bb lors de congr\u00e8s majeurs<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0c1a1f7 elementor-widget elementor-widget-text-editor\" data-id=\"0c1a1f7\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><a href=\"https:\/\/www.maatpharma.com\/fr\/key-results-from-the-chronos-multicentre-retrospective-cohort-study-describing-patient-outcomes-in-third-line-acute-gastrointestinal-gvhd\/\">Clausen J. <em>et al.<\/em> (2026). Key Results from the CHRONOS Multicentre Retrospective Cohort Study Describing Patient Outcomes in Third-Line Acute Gastrointestinal GvHD<\/a><\/li><li><a href=\"https:\/\/www.maatpharma.com\/fr\/maat033-for-gut-microbiota-optimization-to-improve-survival-after-allogenic-hct-the-phoebus-trial\/\">Malard F. <em>et al.<\/em> (2026). MaaT033 For Gut Microbiota Optimization To Improve Survival After Allogenic HCT: The PHOEBUS Trial<\/a><\/li><li><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/12\/2024_PosterSFGMTC_PHOEBUS-Final-3.pdf\">Malard F. <em>et al.<\/em>\u00a0(2024). MaaT033 pour assurer un microbiote intestinal optimal afin d\u2019am\u00e9liorer la survie des patients recevant une allo-CSH : Essai PHOEBUS. SFGM-TC Congress (French only)<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/12\/SEHH-2024-_Poster-Phoebus-VF.pdf\">Malard F.\u00a0<em>et al.<\/em>\u00a0(2024). PHOEBUS Trial: an international, randomized, double-blind, multicenter phase IIb study evaluating MaaT033, oral allogeic fecal microbiotherapy, in patients undergoing allo-HSCT to improve overall survival. SEHH Congress (Spanish only)<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/11\/221102_PosterIHMC_HeraclesEAP_v2.0.pdf\">Malard F.\u00a0<em>et al.<\/em>\u00a0(2022). Pooled allogenic fecal microbiotherapy MaaT013 for the treatment of steroid-refractory gastrointestinal acute graft versus-host disease: results from the phase IIa HERACLES study and expanded access program. IHMC congress<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/11\/221003_Poster_IHMC_MaaT013_v2-1.pdf\">Gasc C.\u00a0<em>et al.\u00a0<\/em>(2022).\u00a0Pooling of faecal material results in standardized and high-richness microbiotherapy products MaaT013 and MaaT033. IHMC congress<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/11\/221102_Poster_IHMC_CMC_V1.0.pdf\">Duquenoy A.<em>et al.\u00a0<\/em>(2022).Development of a culture manufacturing process preserving the profile of gut microbiota for therapeutic purposes. IHMC congress<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136604.html\">Malard F.\u00a0<em>et al.<\/em>\u00a0(2019). Successful and safe treatment of intestinal Graft-versus-Host Disease (GvHD) with pooled-donor full ecosystem microbiota biotherapeutics.\u00a0<em>Blood<\/em>. ASH congress<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/\/wp-content\/uploads\/2019\/03\/EBMT-2019-POSTER-B137.pdf\">Malard F.\u00a0<em>et al.<\/em>\u00a0(2019). Heracles: a phase II single-arm prospective study to assess the efficacy of fecal microbiota transfer (FMT) in the treatment of steroid-refractory gastro-intestinal predominant aGVHD post allo-HSCT.\u00a0<em>EBMT congress\u00a0<\/em><\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/\/wp-content\/uploads\/2019\/01\/Poster-ASH-dec-2018-MaaT-Pharma.pdf\">Mohty M.\u00a0<em>et al.<\/em>\u00a0(2018). The Odyssee Study: Prevention of Dysbiosis Complications with Autologous Fecal Microbiota Transfer (FMT) in Acute Myeloid Leukemia (AML) Patients Undergoing Intensive Treatment: Results of a Prospective Multicenter Trial.\u00a0<em>Blood<\/em>.\u00a0<em>ASH congress<\/em><\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/ashpublications.org\/blood\/article\/132\/Supplement%201\/1444\/262968\/The-Odyssee-Study-Prevention-of-Dysbiosis\">Mohty M.\u00a0<em>et al.<\/em>\u00a0(2017). Prevention of dysbiosis complications with autologous fecal microbiota transplantation (auto-FMT) in acute myeloid leukemia (AML) patients undergoing intensive treatment (ODYSSEE study): first results of a prospective multicenter trial.\u00a0<em>Blood.<\/em>\u00a0<em>ASH congress<\/em><\/a><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-133a6ed elementor-widget elementor-widget-heading\" data-id=\"133a6ed\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h3 class=\"elementor-heading-title elementor-size-default\">Communications orales lors de Congr\u00e8s majeurs<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-ec21294 elementor-widget elementor-widget-text-editor\" data-id=\"ec21294\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<ul><li><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/03\/EBMT-2026_MaaT013_Malard.pdf\">Malard F. (2026). MaaT013 for Ruxolitinib-Refractory Acute Graft-versus-Host Disease with Gastrointestinal Involvement: Results from the ARES Phase III Trial. EBMT Congress<\/a><\/li><li><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/03\/ASH2025_Pr-Malard_ARES-Phase3-Trial_MaaT013_Final.pdf\">Malard F. (2025). MaaT013 for Ruxolitinib-Refractory Acute Graft-versus-Host Disease with Gastrointestinal Involvement: Results from the ARES Phase III Trial. ASH Congress<\/a><\/li><li><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/12\/SFGMTC-2024-EAP-Malard-1.0.pdf\">Malard F. <em>et al<\/em>. (2024). Pooled fecal allogenic microbiotherapy for refractory gastrointestinal acute graft-versus-host disease: results from the early access program in Europe. SFGM-TC Congress<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2024\/12\/Maat13_SEHH_2024.pdf\">Sanz J. (2024) Allogenic fecal microbiotherapy as a treatment for refractory Graft-versus-Host acute gastrointestinal disease: results of the EAP in Europe. SEHH Congress<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/fr\/maat-pharma-presente-a-loccasion-de-la-63eme-rencontre-annuelle-de-lash-des-resultats-cliniques-prometteurs-issus-de-76-patients-atteints-de-la-maladie-du-greffon-contre-l\/\">Malard F.\u00a0<em>et al<\/em>. (2021). 262 Pooled Allogenic Fecal Microbiotherapy MaaT013 for the Treatment of Steroid-Refractory Gastrointestinal Acute Graft-Versus-Host Disease: Results from the Phase IIa Heracles Study and Expanded Access Program. ASH congress<\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/09\/20210311_MaaT_EBMT-platform-presentation-acceptance_FINAL.pdf\">Malard F.\u00a0<em>et al<\/em>. (2021). Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use\/Expanded Access Treatment Program.\u00a0<em>EBMT congress<\/em><\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper136604.html\">Malard F.\u00a0<em>et al<\/em>. (2020). Successful and Safe Treatment of Intestinal Graft-Versus-Host Disease (GvHD) with Pooled-Donor Full Ecosystem Microbiota Biotherapeutic: Results from a 29 Patient-Cohort of a Compassionate Use\/Expanded Access Treatment Program.\u00a0<em>Blood<\/em>.\u00a0<em>ASH congress<\/em><\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/2020_EBMT_Dr-Malard-GvHD-MaaT013-Poster-VF.pdf\">Malard F.\u00a0<em>et al<\/em>. (2020). Successful and safe treatment of intestinal graft-versus-host disease (GvHD) with pooled-donor full ecosystem microbiota biotherapeutics.\u00a0<em>EBMT congress<\/em><\/a><\/li><li><i class=\"icon-default-style icon-salient-thin-line accent-color\"><\/i><a href=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2022\/01\/ASH-poster-2624-grand-format.pdf\">Malard F.\u00a0<em>et al.<\/em>\u00a0(2019). The odyssee study: prevention of dysbiosis complications with autologous fecal microbiota transfer in acute myeloid leukemia patients undergoing intensive-treatment: results of a prospective multicenter trial.\u00a0<em>EBMT congress<\/em><\/a><\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>Pionniers de l\u2019approche \u00e9cosyst\u00e8me complet Nous d\u00e9veloppons une nouvelle classe de th\u00e9rapies \u00e0 base de microbiote, pour relever le d\u00e9fi d\u2019indications \u00e0 fort besoin m\u00e9dical en oncologie Menu Vue d&rsquo;ensemble Xervyteg\u00ae (MaaT013) MaaT033 MaaT034 MaaT03X Publications scientifiques Le portefeuille de MaaT Pharma exploite deux approches : Restaurer le microbiote en h\u00e9mato-oncologie :Les th\u00e9rapies de MaaT Pharma pour le traitement de la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGVH) et la pr\u00e9vention des complications de la greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) ont pour but de\u00a0restaurer les fonctions physiologiques d\u2019un\u00a0microbiote sain\u00a0afin de corriger les effets de facteurs de stress comme les antibiotiques et les chimioth\u00e9rapies. Restaurer et moduler le microbiote en immuno-oncologie :Les th\u00e9rapies de MaaT Pharma pour le traitement des tumeurs solides ont pour objectif de restaurer et moduler le microbiote , dans le but d\u2019am\u00e9liorer la r\u00e9ponse aux inhibiteurs de points de contr\u00f4le immunitaires, traitements souvent incontournables dans ces indications. Xervyteg\u00ae (MaaT013) : traiter la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGvH) Xervyteg\u00ae (MaaT013): R\u00e9sultats positifs de l&rsquo;\u00e9tude pivotale \u2013 Plus d\u2019informations Le besoin m\u00e9dical La\u00a0maladie aigu\u00eb du greffon contre l\u2019h\u00f4te (aGvH)\u00a0survient chez les patients dans les 100 jours apr\u00e8s une greffe de cellules souches ou de moelle osseuse. Les cellules greff\u00e9es \u00ab\u00a0attaquent\u00a0\u00bb le receveur, provoquant une inflammation de la peau, du foie et\/ou du tractus gastro-intestinal et entra\u00eenant une morbidit\u00e9 et une mortalit\u00e9 \u00e9lev\u00e9es. L\u2019atteinte gastro-intestinale notamment est associ\u00e9e \u00e0 des complications graves telles que diarrh\u00e9es intenses, douleurs abdominales, h\u00e9morragies intestinales et mettant en jeu le pronostic vital du patient, avec un risque de mortalit\u00e9 accru, en raison des difficult\u00e9s li\u00e9es \u00e0 la prise en charge d\u2019une inflammation gastro-intestinale s\u00e9v\u00e8re et des risques associ\u00e9s d\u2019infection, de malnutrition et de d\u00e9faillance d\u2019organes. 30-50% des patients recevant une allo-GCSH d\u00e9veloppent une aGvH. 70-80% Taux de mortalit\u00e9 constat\u00e9 apr\u00e8s 1 an chez les patients avec une aGvH cortico-r\u00e9sistante. Env.10000 cas d\u2019aGvH en 2018 aux USA, UK, France, Allemagne, Italie, Espagne et Japon. Le traitement th\u00e9rapeutique standard de premi\u00e8re ligne pour traiter l\u2019aGvH est le recours aux st\u00e9ro\u00efdes. Si les patients ne r\u00e9pondent pas aux st\u00e9ro\u00efdes, ils sont consid\u00e9r\u00e9s comme r\u00e9sistants (SR) et d\u2019autres traitements peuvent \u00eatre administr\u00e9s comme le ruxolitinib. La perte de diversit\u00e9 du microbiote intestinal, li\u00e9e aux chimioth\u00e9rapies et antibioth\u00e9rapies intensives que les patients re\u00e7oivent avant la greffe de cellules souches, est pr\u00e9dictive de l\u2019incidence de la maladie du greffon contre l\u2019h\u00f4te et est \u00e9galement associ\u00e9e \u00e0 des taux de survie plus bas apr\u00e8s une allo-GCSH. 2,3, 4, En apprendre plus sur les cancers du sang et l&rsquo;aGvH Restauration du microbiote avec Xervyteg\u00ae (MaaT013) : un produit \u00e0 densit\u00e9 maximale pour une implantation d\u2019esp\u00e8ces b\u00e9n\u00e9fiques rapide dans les situations d\u2019urgence Xervyteg\u00ae (MaaT013) est une th\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet (MET) d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes , qui contient le ButycoreTM , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires. Xervyteg\u00ae (MaaT013) a obtenu la d\u00e9signation de m\u00e9dicament orphelin de la part de la FDA et de l\u2019EMA. Xervyteg\u00ae (MaaT013) est un candidat-m\u00e9dicament issu du microbiote actuellement en cours d\u2019examen r\u00e9glementaire en Europe pour le traitement de la\u00a0maladie aigu\u00eb du greffon contre l\u2019h\u00f4te avec atteinte gastro-intestinale (GI-aGvH). Ce traitement a \u00e9t\u00e9 \u00e9valu\u00e9 dans le cadre de l\u2019essai clinique pivotal ARES (NCT04769895), le premier essai pivotal mondial portant sur une th\u00e9rapie issue du microbiote en h\u00e9mato-oncologie. L\u2019essai\u00a0ARES\u00a0a recrut\u00e9 en Europe\u00a066 patients atteints de GI-aGvH r\u00e9fractaire\u00a0aux traitements de premi\u00e8re ligne par cortico\u00efdes et de deuxi\u00e8me ligne par\u00a0ruxolitinib, les standards actuels de prise en charge. 300+ patients trait\u00e9s avec MaaT013 \u00e0 ce jour. \u00c9tapes cliniques majeures :\u2013\u00a0Premier patient trait\u00e9 dans l\u2019essai clinique pivotal ARES\u2013\u00a0Avis positif suite \u00e0 l\u2019\u00e9valuation du DSMB* pour l\u2019essai pivotal en cours,\u00a0confirmant le profil de s\u00e9curit\u00e9\u2013\u00a0R\u00e9sultats principaux positifs de l\u2019\u00e9tude pivotale ARES \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l\u2019h\u00f4te,\u00a0montrant une forte efficacit\u00e9 et un profil de s\u00e9curit\u00e9 favorable\u2013\u00a0Conclusion positive de l\u2019examen final du DSMB pour l\u2019essai clinique pivotal, confirmant un profil b\u00e9n\u00e9fice-risque favorable\u2013\u00a0Dossier de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) soumis \u00e0 l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA)\u00a0en juin 2025 pour le traitement de la GI-aGvH Si approuv\u00e9, Xervyteg\u00ae (MaaT013) a le potentiel de devenir le premier m\u00e9dicament issu du microbiote approuv\u00e9 par l\u2019EMA, et le premier au niveau mondial dans une indication en h\u00e9matologie. MaaT033 : la capsule de microbiote \u00e0 \u00e9cosyst\u00e8me complet, en forme orale, pour des traitements adjuvants Le besoin m\u00e9dical La transplantation de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) est une proc\u00e9dure susceptible de sauver la vie de patients souffrant de cancers du sang comme la leuc\u00e9mie aig\u00fce my\u00e9lo\u00efde. Malheureusement, elle peut \u00e9galement \u00eatre associ\u00e9e \u00e0 des complications graves, comme des infections, la maladie du greffon contre l\u2019h\u00f4te, ou la neutrop\u00e9nie, qui contribuent \u00e0 une mortalit\u00e9 de l\u2019ordre de 34%6, un an apr\u00e8s la proc\u00e9dure chez les patients de plus de 50 ans. Env.20000 patients re\u00e7oivent une premi\u00e8re allo-GCSH chaque ann\u00e9e aux USA, UK, France, Allemagne, Italie, Espagne et Japon. MaaT033 pour am\u00e9liorer la survie des patients recevant des allo-GSCH La perte de diversit\u00e9 du microbiote intestinal li\u00e9e \u00e0 la chimioth\u00e9rapie et aux antibiotiques utilis\u00e9s en amont de l\u2019allo-GSCH est pr\u00e9dictive de la mortalit\u00e9 des patients soumis \u00e0 la proc\u00e9dure, ainsi que du risque de d\u00e9velopper une maladie du greffon contre l\u2019h\u00f4te et des infections.2 3 4 7 MaaT033 est une th\u00e9rapie issue du microbiote (MET) sous forme orale, d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes , qui contient le ButycoreTM , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires. Le mode d\u2019action suppos\u00e9 de MaaT033 est immuno-modulateur : Restauration de la richesse et de la diversit\u00e9 microbiennes et production d\u2019acides gras \u00e0 cha\u00eene courte immunomodulateurs, qui r\u00e9gulent positivement les cellules TReg, et participent ainsi \u00e0 la restauration de l\u2019hom\u00e9ostase immunitaires. Restauration de la barri\u00e8re intestinale, qui joue un r\u00f4le cl\u00e9 dans la pr\u00e9vention des infections et en particulier celles li\u00e9es aux bact\u00e9ries multi-r\u00e9sistantes (MDRB) Statut de d\u00e9veloppement de MaaT033 Des r\u00e9sultats positifs de<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-4052","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pipeline - MaaT Pharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/pipeline\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pipeline - MaaT Pharma\" \/>\n<meta property=\"og:description\" content=\"Pionniers de l\u2019approche \u00e9cosyst\u00e8me complet Nous d\u00e9veloppons une nouvelle classe de th\u00e9rapies \u00e0 base de microbiote, pour relever le d\u00e9fi d\u2019indications \u00e0 fort besoin m\u00e9dical en oncologie Menu Vue d&rsquo;ensemble Xervyteg\u00ae (MaaT013) MaaT033 MaaT034 MaaT03X Publications scientifiques Le portefeuille de MaaT Pharma exploite deux approches : Restaurer le microbiote en h\u00e9mato-oncologie :Les th\u00e9rapies de MaaT Pharma pour le traitement de la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGVH) et la pr\u00e9vention des complications de la greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) ont pour but de\u00a0restaurer les fonctions physiologiques d\u2019un\u00a0microbiote sain\u00a0afin de corriger les effets de facteurs de stress comme les antibiotiques et les chimioth\u00e9rapies. Restaurer et moduler le microbiote en immuno-oncologie :Les th\u00e9rapies de MaaT Pharma pour le traitement des tumeurs solides ont pour objectif de restaurer et moduler le microbiote , dans le but d\u2019am\u00e9liorer la r\u00e9ponse aux inhibiteurs de points de contr\u00f4le immunitaires, traitements souvent incontournables dans ces indications. Xervyteg\u00ae (MaaT013) : traiter la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGvH) Xervyteg\u00ae (MaaT013): R\u00e9sultats positifs de l&rsquo;\u00e9tude pivotale \u2013 Plus d\u2019informations Le besoin m\u00e9dical La\u00a0maladie aigu\u00eb du greffon contre l\u2019h\u00f4te (aGvH)\u00a0survient chez les patients dans les 100 jours apr\u00e8s une greffe de cellules souches ou de moelle osseuse. Les cellules greff\u00e9es \u00ab\u00a0attaquent\u00a0\u00bb le receveur, provoquant une inflammation de la peau, du foie et\/ou du tractus gastro-intestinal et entra\u00eenant une morbidit\u00e9 et une mortalit\u00e9 \u00e9lev\u00e9es. L\u2019atteinte gastro-intestinale notamment est associ\u00e9e \u00e0 des complications graves telles que diarrh\u00e9es intenses, douleurs abdominales, h\u00e9morragies intestinales et mettant en jeu le pronostic vital du patient, avec un risque de mortalit\u00e9 accru, en raison des difficult\u00e9s li\u00e9es \u00e0 la prise en charge d\u2019une inflammation gastro-intestinale s\u00e9v\u00e8re et des risques associ\u00e9s d\u2019infection, de malnutrition et de d\u00e9faillance d\u2019organes. 30-50% des patients recevant une allo-GCSH d\u00e9veloppent une aGvH. 70-80% Taux de mortalit\u00e9 constat\u00e9 apr\u00e8s 1 an chez les patients avec une aGvH cortico-r\u00e9sistante. Env.10000 cas d\u2019aGvH en 2018 aux USA, UK, France, Allemagne, Italie, Espagne et Japon. Le traitement th\u00e9rapeutique standard de premi\u00e8re ligne pour traiter l\u2019aGvH est le recours aux st\u00e9ro\u00efdes. Si les patients ne r\u00e9pondent pas aux st\u00e9ro\u00efdes, ils sont consid\u00e9r\u00e9s comme r\u00e9sistants (SR) et d\u2019autres traitements peuvent \u00eatre administr\u00e9s comme le ruxolitinib. La perte de diversit\u00e9 du microbiote intestinal, li\u00e9e aux chimioth\u00e9rapies et antibioth\u00e9rapies intensives que les patients re\u00e7oivent avant la greffe de cellules souches, est pr\u00e9dictive de l\u2019incidence de la maladie du greffon contre l\u2019h\u00f4te et est \u00e9galement associ\u00e9e \u00e0 des taux de survie plus bas apr\u00e8s une allo-GCSH. 2,3, 4, En apprendre plus sur les cancers du sang et l&rsquo;aGvH Restauration du microbiote avec Xervyteg\u00ae (MaaT013) : un produit \u00e0 densit\u00e9 maximale pour une implantation d\u2019esp\u00e8ces b\u00e9n\u00e9fiques rapide dans les situations d\u2019urgence Xervyteg\u00ae (MaaT013) est une th\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet (MET) d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes , qui contient le ButycoreTM , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires. Xervyteg\u00ae (MaaT013) a obtenu la d\u00e9signation de m\u00e9dicament orphelin de la part de la FDA et de l\u2019EMA. Xervyteg\u00ae (MaaT013) est un candidat-m\u00e9dicament issu du microbiote actuellement en cours d\u2019examen r\u00e9glementaire en Europe pour le traitement de la\u00a0maladie aigu\u00eb du greffon contre l\u2019h\u00f4te avec atteinte gastro-intestinale (GI-aGvH). Ce traitement a \u00e9t\u00e9 \u00e9valu\u00e9 dans le cadre de l\u2019essai clinique pivotal ARES (NCT04769895), le premier essai pivotal mondial portant sur une th\u00e9rapie issue du microbiote en h\u00e9mato-oncologie. L\u2019essai\u00a0ARES\u00a0a recrut\u00e9 en Europe\u00a066 patients atteints de GI-aGvH r\u00e9fractaire\u00a0aux traitements de premi\u00e8re ligne par cortico\u00efdes et de deuxi\u00e8me ligne par\u00a0ruxolitinib, les standards actuels de prise en charge. 300+ patients trait\u00e9s avec MaaT013 \u00e0 ce jour. \u00c9tapes cliniques majeures :\u2013\u00a0Premier patient trait\u00e9 dans l\u2019essai clinique pivotal ARES\u2013\u00a0Avis positif suite \u00e0 l\u2019\u00e9valuation du DSMB* pour l\u2019essai pivotal en cours,\u00a0confirmant le profil de s\u00e9curit\u00e9\u2013\u00a0R\u00e9sultats principaux positifs de l\u2019\u00e9tude pivotale ARES \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l\u2019h\u00f4te,\u00a0montrant une forte efficacit\u00e9 et un profil de s\u00e9curit\u00e9 favorable\u2013\u00a0Conclusion positive de l\u2019examen final du DSMB pour l\u2019essai clinique pivotal, confirmant un profil b\u00e9n\u00e9fice-risque favorable\u2013\u00a0Dossier de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) soumis \u00e0 l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA)\u00a0en juin 2025 pour le traitement de la GI-aGvH Si approuv\u00e9, Xervyteg\u00ae (MaaT013) a le potentiel de devenir le premier m\u00e9dicament issu du microbiote approuv\u00e9 par l\u2019EMA, et le premier au niveau mondial dans une indication en h\u00e9matologie. MaaT033 : la capsule de microbiote \u00e0 \u00e9cosyst\u00e8me complet, en forme orale, pour des traitements adjuvants Le besoin m\u00e9dical La transplantation de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) est une proc\u00e9dure susceptible de sauver la vie de patients souffrant de cancers du sang comme la leuc\u00e9mie aig\u00fce my\u00e9lo\u00efde. Malheureusement, elle peut \u00e9galement \u00eatre associ\u00e9e \u00e0 des complications graves, comme des infections, la maladie du greffon contre l\u2019h\u00f4te, ou la neutrop\u00e9nie, qui contribuent \u00e0 une mortalit\u00e9 de l\u2019ordre de 34%6, un an apr\u00e8s la proc\u00e9dure chez les patients de plus de 50 ans. Env.20000 patients re\u00e7oivent une premi\u00e8re allo-GCSH chaque ann\u00e9e aux USA, UK, France, Allemagne, Italie, Espagne et Japon. MaaT033 pour am\u00e9liorer la survie des patients recevant des allo-GSCH La perte de diversit\u00e9 du microbiote intestinal li\u00e9e \u00e0 la chimioth\u00e9rapie et aux antibiotiques utilis\u00e9s en amont de l\u2019allo-GSCH est pr\u00e9dictive de la mortalit\u00e9 des patients soumis \u00e0 la proc\u00e9dure, ainsi que du risque de d\u00e9velopper une maladie du greffon contre l\u2019h\u00f4te et des infections.2 3 4 7 MaaT033 est une th\u00e9rapie issue du microbiote (MET) sous forme orale, d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes , qui contient le ButycoreTM , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires. Le mode d\u2019action suppos\u00e9 de MaaT033 est immuno-modulateur : Restauration de la richesse et de la diversit\u00e9 microbiennes et production d\u2019acides gras \u00e0 cha\u00eene courte immunomodulateurs, qui r\u00e9gulent positivement les cellules TReg, et participent ainsi \u00e0 la restauration de l\u2019hom\u00e9ostase immunitaires. Restauration de la barri\u00e8re intestinale, qui joue un r\u00f4le cl\u00e9 dans la pr\u00e9vention des infections et en particulier celles li\u00e9es aux bact\u00e9ries multi-r\u00e9sistantes (MDRB) Statut de d\u00e9veloppement de MaaT033 Des r\u00e9sultats positifs de\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/pipeline\/\" \/>\n<meta property=\"og:site_name\" content=\"MaaT Pharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-15T14:21:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1704\" \/>\n\t<meta property=\"og:image:height\" content=\"1080\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"26 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/\",\"name\":\"Pipeline - MaaT Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Pipeline-FR-09.2025.png\",\"datePublished\":\"2021-10-01T06:12:27+00:00\",\"dateModified\":\"2026-04-15T14:21:30+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Pipeline-FR-09.2025.png\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Pipeline-FR-09.2025.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/pipeline\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"MaaT Pharma\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pipeline - MaaT Pharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/pipeline\/","og_locale":"fr_FR","og_type":"article","og_title":"Pipeline - MaaT Pharma","og_description":"Pionniers de l\u2019approche \u00e9cosyst\u00e8me complet Nous d\u00e9veloppons une nouvelle classe de th\u00e9rapies \u00e0 base de microbiote, pour relever le d\u00e9fi d\u2019indications \u00e0 fort besoin m\u00e9dical en oncologie Menu Vue d&rsquo;ensemble Xervyteg\u00ae (MaaT013) MaaT033 MaaT034 MaaT03X Publications scientifiques Le portefeuille de MaaT Pharma exploite deux approches : Restaurer le microbiote en h\u00e9mato-oncologie :Les th\u00e9rapies de MaaT Pharma pour le traitement de la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGVH) et la pr\u00e9vention des complications de la greffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) ont pour but de\u00a0restaurer les fonctions physiologiques d\u2019un\u00a0microbiote sain\u00a0afin de corriger les effets de facteurs de stress comme les antibiotiques et les chimioth\u00e9rapies. Restaurer et moduler le microbiote en immuno-oncologie :Les th\u00e9rapies de MaaT Pharma pour le traitement des tumeurs solides ont pour objectif de restaurer et moduler le microbiote , dans le but d\u2019am\u00e9liorer la r\u00e9ponse aux inhibiteurs de points de contr\u00f4le immunitaires, traitements souvent incontournables dans ces indications. Xervyteg\u00ae (MaaT013) : traiter la maladie aig\u00fce du greffon contre l\u2019h\u00f4te (aGvH) Xervyteg\u00ae (MaaT013): R\u00e9sultats positifs de l&rsquo;\u00e9tude pivotale \u2013 Plus d\u2019informations Le besoin m\u00e9dical La\u00a0maladie aigu\u00eb du greffon contre l\u2019h\u00f4te (aGvH)\u00a0survient chez les patients dans les 100 jours apr\u00e8s une greffe de cellules souches ou de moelle osseuse. Les cellules greff\u00e9es \u00ab\u00a0attaquent\u00a0\u00bb le receveur, provoquant une inflammation de la peau, du foie et\/ou du tractus gastro-intestinal et entra\u00eenant une morbidit\u00e9 et une mortalit\u00e9 \u00e9lev\u00e9es. L\u2019atteinte gastro-intestinale notamment est associ\u00e9e \u00e0 des complications graves telles que diarrh\u00e9es intenses, douleurs abdominales, h\u00e9morragies intestinales et mettant en jeu le pronostic vital du patient, avec un risque de mortalit\u00e9 accru, en raison des difficult\u00e9s li\u00e9es \u00e0 la prise en charge d\u2019une inflammation gastro-intestinale s\u00e9v\u00e8re et des risques associ\u00e9s d\u2019infection, de malnutrition et de d\u00e9faillance d\u2019organes. 30-50% des patients recevant une allo-GCSH d\u00e9veloppent une aGvH. 70-80% Taux de mortalit\u00e9 constat\u00e9 apr\u00e8s 1 an chez les patients avec une aGvH cortico-r\u00e9sistante. Env.10000 cas d\u2019aGvH en 2018 aux USA, UK, France, Allemagne, Italie, Espagne et Japon. Le traitement th\u00e9rapeutique standard de premi\u00e8re ligne pour traiter l\u2019aGvH est le recours aux st\u00e9ro\u00efdes. Si les patients ne r\u00e9pondent pas aux st\u00e9ro\u00efdes, ils sont consid\u00e9r\u00e9s comme r\u00e9sistants (SR) et d\u2019autres traitements peuvent \u00eatre administr\u00e9s comme le ruxolitinib. La perte de diversit\u00e9 du microbiote intestinal, li\u00e9e aux chimioth\u00e9rapies et antibioth\u00e9rapies intensives que les patients re\u00e7oivent avant la greffe de cellules souches, est pr\u00e9dictive de l\u2019incidence de la maladie du greffon contre l\u2019h\u00f4te et est \u00e9galement associ\u00e9e \u00e0 des taux de survie plus bas apr\u00e8s une allo-GCSH. 2,3, 4, En apprendre plus sur les cancers du sang et l&rsquo;aGvH Restauration du microbiote avec Xervyteg\u00ae (MaaT013) : un produit \u00e0 densit\u00e9 maximale pour une implantation d\u2019esp\u00e8ces b\u00e9n\u00e9fiques rapide dans les situations d\u2019urgence Xervyteg\u00ae (MaaT013) est une th\u00e9rapie \u00e0 \u00e9cosyst\u00e8me complet (MET) d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes , qui contient le ButycoreTM , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires. Xervyteg\u00ae (MaaT013) a obtenu la d\u00e9signation de m\u00e9dicament orphelin de la part de la FDA et de l\u2019EMA. Xervyteg\u00ae (MaaT013) est un candidat-m\u00e9dicament issu du microbiote actuellement en cours d\u2019examen r\u00e9glementaire en Europe pour le traitement de la\u00a0maladie aigu\u00eb du greffon contre l\u2019h\u00f4te avec atteinte gastro-intestinale (GI-aGvH). Ce traitement a \u00e9t\u00e9 \u00e9valu\u00e9 dans le cadre de l\u2019essai clinique pivotal ARES (NCT04769895), le premier essai pivotal mondial portant sur une th\u00e9rapie issue du microbiote en h\u00e9mato-oncologie. L\u2019essai\u00a0ARES\u00a0a recrut\u00e9 en Europe\u00a066 patients atteints de GI-aGvH r\u00e9fractaire\u00a0aux traitements de premi\u00e8re ligne par cortico\u00efdes et de deuxi\u00e8me ligne par\u00a0ruxolitinib, les standards actuels de prise en charge. 300+ patients trait\u00e9s avec MaaT013 \u00e0 ce jour. \u00c9tapes cliniques majeures :\u2013\u00a0Premier patient trait\u00e9 dans l\u2019essai clinique pivotal ARES\u2013\u00a0Avis positif suite \u00e0 l\u2019\u00e9valuation du DSMB* pour l\u2019essai pivotal en cours,\u00a0confirmant le profil de s\u00e9curit\u00e9\u2013\u00a0R\u00e9sultats principaux positifs de l\u2019\u00e9tude pivotale ARES \u00e9valuant MaaT013 dans la maladie aigu\u00eb du greffon contre l\u2019h\u00f4te,\u00a0montrant une forte efficacit\u00e9 et un profil de s\u00e9curit\u00e9 favorable\u2013\u00a0Conclusion positive de l\u2019examen final du DSMB pour l\u2019essai clinique pivotal, confirmant un profil b\u00e9n\u00e9fice-risque favorable\u2013\u00a0Dossier de demande d\u2019autorisation de mise sur le march\u00e9 (AMM) soumis \u00e0 l\u2019Agence europ\u00e9enne des m\u00e9dicaments (EMA)\u00a0en juin 2025 pour le traitement de la GI-aGvH Si approuv\u00e9, Xervyteg\u00ae (MaaT013) a le potentiel de devenir le premier m\u00e9dicament issu du microbiote approuv\u00e9 par l\u2019EMA, et le premier au niveau mondial dans une indication en h\u00e9matologie. MaaT033 : la capsule de microbiote \u00e0 \u00e9cosyst\u00e8me complet, en forme orale, pour des traitements adjuvants Le besoin m\u00e9dical La transplantation de cellules souches h\u00e9matopo\u00ef\u00e9tiques allog\u00e9niques (allo-GCSH) est une proc\u00e9dure susceptible de sauver la vie de patients souffrant de cancers du sang comme la leuc\u00e9mie aig\u00fce my\u00e9lo\u00efde. Malheureusement, elle peut \u00e9galement \u00eatre associ\u00e9e \u00e0 des complications graves, comme des infections, la maladie du greffon contre l\u2019h\u00f4te, ou la neutrop\u00e9nie, qui contribuent \u00e0 une mortalit\u00e9 de l\u2019ordre de 34%6, un an apr\u00e8s la proc\u00e9dure chez les patients de plus de 50 ans. Env.20000 patients re\u00e7oivent une premi\u00e8re allo-GCSH chaque ann\u00e9e aux USA, UK, France, Allemagne, Italie, Espagne et Japon. MaaT033 pour am\u00e9liorer la survie des patients recevant des allo-GSCH La perte de diversit\u00e9 du microbiote intestinal li\u00e9e \u00e0 la chimioth\u00e9rapie et aux antibiotiques utilis\u00e9s en amont de l\u2019allo-GSCH est pr\u00e9dictive de la mortalit\u00e9 des patients soumis \u00e0 la proc\u00e9dure, ainsi que du risque de d\u00e9velopper une maladie du greffon contre l\u2019h\u00f4te et des infections.2 3 4 7 MaaT033 est une th\u00e9rapie issue du microbiote (MET) sous forme orale, d\u00e9riv\u00e9e de donneurs sains, standardis\u00e9e, \u00e0 haute richesse et haute diversit\u00e9 bact\u00e9riennes , qui contient le ButycoreTM , un groupe de bact\u00e9ries connues pour produire des acides gras \u00e0 cha\u00eene courte aux propri\u00e9t\u00e9s anti-inflammatoires. Le mode d\u2019action suppos\u00e9 de MaaT033 est immuno-modulateur : Restauration de la richesse et de la diversit\u00e9 microbiennes et production d\u2019acides gras \u00e0 cha\u00eene courte immunomodulateurs, qui r\u00e9gulent positivement les cellules TReg, et participent ainsi \u00e0 la restauration de l\u2019hom\u00e9ostase immunitaires. Restauration de la barri\u00e8re intestinale, qui joue un r\u00f4le cl\u00e9 dans la pr\u00e9vention des infections et en particulier celles li\u00e9es aux bact\u00e9ries multi-r\u00e9sistantes (MDRB) Statut de d\u00e9veloppement de MaaT033 Des r\u00e9sultats positifs de","og_url":"https:\/\/www.maatpharma.com\/pipeline\/","og_site_name":"MaaT Pharma","article_modified_time":"2026-04-15T14:21:30+00:00","og_image":[{"width":1704,"height":1080,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"26 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/pipeline\/","url":"https:\/\/www.maatpharma.com\/pipeline\/","name":"Pipeline - MaaT Pharma","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/pipeline\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/pipeline\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025.png","datePublished":"2021-10-01T06:12:27+00:00","dateModified":"2026-04-15T14:21:30+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/pipeline\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/pipeline\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/pipeline\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025.png","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2026\/01\/Pipeline-FR-09.2025.png"},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/pipeline\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"MaaT Pharma","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages\/4052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4052"}],"version-history":[{"count":33,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages\/4052\/revisions"}],"predecessor-version":[{"id":25650,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/pages\/4052\/revisions\/25650"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}